Altimmune AI Price Prediction

Altimmune is currently unprofitable, as reflected by its negative EPS and PE ratio. The lack of positive earnings indicates that the company is still in a cash‑consuming phase, likely reliant on external financing rather than internally generated cash flow. Until there is a clear path to profitability or meaningful revenue growth, the financial profile remains high risk.

• Negative EPS of -0.92 signals ongoing losses and an absence of sustainable profitability.
• A PE ratio of -2.95 confirms that the stock is not supported by current earnings and is instead valued on expectations of future success.
• Without evidence of strong revenue growth or improving margins, the financial picture suggests continued dependence on capital markets and a higher risk profile for equity holders.

Altimmune’s share price at $2.71 is trading well below its 200‑day moving average of $3.94, indicating a sustained downtrend. The 12.3% decline over the last month reinforces negative momentum and suggests weak investor confidence. From a technical standpoint, the stock is underperforming and lacks signs of a durable reversal so far.

• Current price of $2.71 is materially below the 200‑day moving average of $3.94, a classic sign of a bearish longer‑term trend.
• A 12.3% price drop in the last month points to recent selling pressure and negative sentiment.
• With the stock trading under its long‑term moving average and no evidence provided of oversold conditions (e.g., low RSI), technicals lean clearly bearish.

Considering the negative earnings profile, the stock’s pronounced weakness versus its 200‑day moving average, and only modest alternative data traction, the overall outlook for Altimmune’s stock skews bearish at this time. While gradual growth in online and social presence is a mild positive, it does not offset the current lack of profitability and negative price momentum. Investors are likely to demand clear clinical or financial catalysts before sentiment materially improves.

• Unprofitable operations combined with a stock trading well below its long‑term moving average point to elevated risk and weak current sentiment.
• Alternative data are mixed and not strong enough to counterbalance the negative technical and financial signals, leaving the near‑term stance on the stock as broadly bearish.